Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CCNH | P51946 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366073 | 1.00 | BRAF (0.52) | BRAFMAPTTP53MCHR1CDK7 | |
| SCHEMBL1368519 | 0.80 | BRAF (0.57) | BRAFCDK7CCNHCDK8PIK3CA | |
| SCHEMBL1368528 | 0.80 | BRAF (0.57) | BRAFCDK7CCNHCDK8PIK3CA | |
| SCHEMBL1366226 | 0.77 | BRAF (0.55) | BRAFMAPTCDK8 | |
| SCHEMBL1366223 | 0.77 | BRAF (0.55) | BRAFMAPTCDK8 | |
| SCHEMBL1367636 | 0.76 | BRAF (0.52) | BRAFMAPTMCHR1CDK7CCNH | |
| SCHEMBL1366164 | 0.74 | BRAF (0.54) | BRAFCDK7CCNHCDK8PIK3CA | |
| SCHEMBL1366159 | 0.74 | BRAF (0.54) | BRAFCDK7CCNHCDK8PIK3CA | |
| SCHEMBL1367889 | 0.72 | BRAF (0.59) | BRAFCDK8PIK3CAMTOR | |
| SCHEMBL1367764 | 0.71 | BRAF (0.58) | BRAFMAPTCDK7CCNHCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| CN-101511828-A | Heteroaryl derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| CN-101511828-A | Heteroaryl derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | BRAF 35/4885MAPT 3427/4885TP53 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.